Preclinical development of immunotherapies

Immunology and Immuno-oncology

© Antineo 2018

Antineo’s panel of immunology assays are designed to help you understand the immunomodulatory effect of your compounds.

The list below is not exhaustive of what we can do, and as scientists, we are always eager to discuss with our clients and to design the experiment that will answer to their need.

T Cell based assays (human and murine cells):

  • T Cell activation assays characterise the activating potential of your compound compared with a standard anti-CD3/CD28 activation. We use either PBMCs or purified T Cells from a healthy donor. The readout of this assay is the production of IFNγ and TNFα by the activated T Cells. This can be quantified by flow cytometry or by ELISA.
  • T Cell proliferation assays measure the pro or anti-proliferative action of your compound by CFSE analysis by flow cytometry. Sub-set phenotyping of CD markers can be added to refine the analyses. This assay can be performed with continuous-monitoring.
  • Cytotoxic T Lymphocytes assays where activated T Cells are incubated with calcein-labelled tumour cells. The calcein release, measured by absorbance with a plate reader, is proportional to the cytotoxic properties of T Cells. This assay can be performed with continuous-monitoring.
  • Mixed Lymphocyte reactions identify agents modulating APC-mediated T Cell activation. The blood of two different healthy donors is used to co-culture T Cells and Dendritic Cells. The readout of T Cells activation and proliferation is the production of IFNγ and TNFα and incorporation of CSFE.

Myeloid cells based assays (human cells):

  • M1/M2 polarisation assays determine the capacity of your compound to reverse immune-suppressive signals. PBMCs or myeloid cells are differentiated in M1 or M2 macrophages.